LORLATINIB

LORLATINIB

Biochem/physiol Actions

Lorlatinib (PF-06463922) is a potent, selective brain-penetrable inhibitor of both anaplastic lymphoma kinase (ALK) and c-ros Oncogene 1 (ROS1) with strong activity against most known ALK and ROS1 mutants identified in patients with crizotinib-resistant disease. It is in clinical trials for the treatment of non–small cell lung cancer (NSCLC).

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Manufacturer Solubility Form Assay Price Quantity
3573567 LORLATINIB white to beige SIGMA-ALDRICH DMSO: 2 mg/mL, clear powder
£474.96 (exc VAT) per 25MG
-
+
3573568 LORLATINIB white to beige SIGMA-ALDRICH DMSO: 2 mg/mL, clear powder
£126.33 (exc VAT) per 5MG
-
+